发明名称 Anti-cancer tamoxifen-melatonin hybrid ligand
摘要 A particularly constructed tamoxifen-melatonin hybrid ligand gives new and unexpectedly improved results in the prevention and treatment of cancer, particularly breast cancer. The hybrid ligand comprises either tamoxifen or 4-hydroxytamoxifen and also melatonin, with the tamoxifen or 4-hydroxytamoxifen and melatonin's being linked by an unsubstituted C2-C6 alkyl linker between the tamoxifen amine and the carbonyl of melatonin.
申请公布号 US8785501(B2) 申请公布日期 2014.07.22
申请号 US201013497954 申请日期 2010.10.12
申请人 Duquesne University of the Holy Spirit 发明人 Witt-Enderby Paula A.;Davis Vicki L.;Lapinsky David
分类号 A01N33/02;A61K31/135;A01N43/38;A61K31/405 主分类号 A01N33/02
代理机构 代理人 Johnson, Esq. Barbara E.
主权项 1. A pharmaceutically active agent consisting essentially of a hybrid ligand of tamoxifen and melatonin linked by a 2-6 carbon alkyl linker conjoining said tamoxifen and said melatonin via a covalent linkage between an amino moiety of said tamoxifen and a hydroxylamino moiety of said melatonin.
地址 Pittsburgh PA US